These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16054931)

  • 21. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
    Gadde KM; Allison DB
    Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
    [No Abstract]   [Full Text] [Related]  

  • 24. Another pill for weight reduction.
    Conti CR
    Clin Cardiol; 2005 Feb; 28(2):59-60. PubMed ID: 15757073
    [No Abstract]   [Full Text] [Related]  

  • 25. Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches.
    Cervino C; Pasquali R; Pagotto U
    Mini Rev Med Chem; 2007 Jan; 7(1):21-30. PubMed ID: 17266634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
    Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
    Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
    [No Abstract]   [Full Text] [Related]  

  • 27. Rimonabant, obesity and diabetes.
    Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Rodés-Cabau J; Cannon CP; Deanfield JE; Després JP; Kastelein JJ; Steinhubl SR; Kapadia S; Yasin M; Ruzyllo W; Gaudin C; Job B; Hu B; Bhatt DL; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1547-60. PubMed ID: 18387931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.
    Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422
    [No Abstract]   [Full Text] [Related]  

  • 30. The endocannabinoid system: potential for reducing cardiometabolic risk.
    Ginsberg HN; Woods SC
    Obesity (Silver Spring); 2009 Oct; 17(10):1821-9. PubMed ID: 19373218
    [No Abstract]   [Full Text] [Related]  

  • 31. Less weight or more hype with rimonabant?
    Drug Ther Bull; 2007 Jun; 45(6):41-3. PubMed ID: 17583228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rimonabant in obese patients with type 2 diabetes.
    Roberfroid D
    Lancet; 2007 Feb; 369(9561):553; author reply 554-5. PubMed ID: 17307092
    [No Abstract]   [Full Text] [Related]  

  • 33. Rimonabant: unique and promising.
    Amsterdam EA
    Prev Cardiol; 2005; 8(3):140. PubMed ID: 16034214
    [No Abstract]   [Full Text] [Related]  

  • 34. [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
    MMW Fortschr Med; 2007 Jun; 149(27-28):8. PubMed ID: 17717874
    [No Abstract]   [Full Text] [Related]  

  • 35. [A drug for therapy of obesity: really only life style? (interview by Dirk Einecke)].
    Wirth A
    MMW Fortschr Med; 2006 Nov; 148(46):17. PubMed ID: 17615781
    [No Abstract]   [Full Text] [Related]  

  • 36. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
    Steinberg BA; Cannon CP
    Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 38. Rehabilitating rimonabant.
    Luft FC
    J Mol Med (Berl); 2013 Jul; 91(7):777-9. PubMed ID: 23591956
    [No Abstract]   [Full Text] [Related]  

  • 39. [In diabetes cannabinoid antagonist kills two birds with one stone].
    MMW Fortschr Med; 2005 Sep; 147(35-36):10. PubMed ID: 16180564
    [No Abstract]   [Full Text] [Related]  

  • 40. [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
    Golay A
    Rev Med Suisse; 2008 Aug; 4(168):1828. PubMed ID: 18814768
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.